Open AccessOral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection
Author(s) -
Estelle Chiari,
W. Jason Weiss,
Michael R. Simon,
S.T. Kießig,
Mark Pulse,
Stephen C. Brown,
Hanne R Gerding,
Maurice Mandago,
Karina Gisch,
Christoph von EichelStreiber
Publication year - 2021
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiab087
Subject(s) - hamster , mesocricetus , immunoglobulin a , clostridioides , immunology , antibody , vancomycin , microbiology and biotechnology , immunization , medicine , immunoglobulin g , biology , pharmacology , bacteria , genetics , staphylococcus aureus
Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.